KEYTRUDA Ovarian Cancer Treatments: FDA Approve...

By João L. Carapinha

February 11, 2026

KEYTRUDA Ovarian Cancer Treatments Gain FDA Nod KEYTRUDA ovarian cancer treatments now include FDA-approved regimens of KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and be...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investmen...
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggress...
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
Innovations in Haematology Cell Therapy at ASH 2025